Endocrine Pharmacology Practice Questions

Q: Which Selective Estrogen Receptor Modulator (SERM) is used in the treatment of Dysfunctional Uterine Bleeding (DUB)?

Ormiloxifene. ***Correct: Ormiloxifene*** - Ormiloxifene is a **selective estrogen receptor modulator (SERM)** specifically approved and used for the management of **dysfunctional uterine bleeding (DUB)**. - It works by acting as an **estrogen antagonist on the endometrium**, which influences the endometrial lining to regulate bleeding patterns and **reduce menstrual blood loss**. - Marketed as **Sevista/Saheli** in India. *Incorrect: Clomiphene* - Clomiphene is primarily used as an **ovulation inducer** in women with infertility due to anovulation [1]. - It acts by blocking estrogen receptors in the hypothalamus, thereby increasing the secretion of gonadotropins [1]. - Not indicated for treatment of DUB. *Incorrect: Raloxifene* - Raloxifene is indicated for the prevention and treatment of **postmenopausal osteoporosis** and the reduction of invasive breast cancer risk in certain high-risk women [1][2]. - It has estrogen-agonist effects on bone and antagonist effects on breast and uterine tissue [1][2]. - Not used for management of DUB. *Incorrect: Tamoxifen* - Tamoxifen is widely used in the treatment of **estrogen receptor-positive breast cancer** in both pre- and postmenopausal women [1][2]. - It acts as an estrogen antagonist in breast tissue but has **estrogen-agonist effects on the endometrium**, which can cause endometrial hyperplasia or cancer [1][2]. - Not indicated for DUB treatment.

Q: Which of the following are medical management options for hyperparathyroidism?

All of the options. ***All of the options*** - **Bisphosphonates**, **calcitonin**, and **plicamycin** (mithramycin) are all therapeutic options used in the medical management of hyperparathyroidism, particularly for reducing hypercalcemia. - These agents work through different mechanisms to lower serum calcium levels, which is a primary goal in managing significant hyperparathyroidism. *Bisphosphonates* - **Bisphosphonates** inhibit osteoclast activity, thereby reducing **bone resorption** and subsequently lowering serum calcium levels. - They are particularly useful for long-term management of hypercalcemia associated with hyperparathyroidism. *Calcitonin* - **Calcitonin** directly inhibits osteoclast activity and increases renal calcium excretion, leading to a relatively rapid, but often short-lived, decrease in serum calcium. - It is often used for the **acute management** of severe hypercalcemia due to its quick onset of action. *Plicamycin* - **Plicamycin** (also known as mithramycin) is an antineoplastic antibiotic that inhibits RNA synthesis and has been shown to reduce serum calcium by inhibiting osteoclast-mediated bone resorption. - Due to its potential for significant side effects, including **renal**, **hepatic**, and **hematologic toxicity**, its use is generally reserved for severe, refractory hypercalcemia.

Q: What is a therapeutic indication for the use of liothyronine?

Resistant depression. ***Resistant depression*** - Liothyronine (T3) can be used as an **adjunctive therapy** for patients with major depressive disorder who have not responded adequately to antidepressant monotherapy. - While the exact mechanism is not fully understood, it's thought to improve antidepressant response by modulating **neurotransmitter systems** and receptor sensitivity in the brain. *Social phobia* - **Social phobia**, or social anxiety disorder, is primarily treated with psychotherapy (e.g., CBT) and medications like **SSRIs** or **SNRIs**. - Liothyronine is **not a primary or adjunctive treatment** for social phobia. *Alzheimer's disease* - **Alzheimer's disease** is a neurodegenerative disorder treated with cholinesterase inhibitors (e.g., donepezil) and NMDA receptor antagonists (e.g., memantine). - There is currently **no established role for liothyronine** in the treatment of Alzheimer's disease. *Cataplexy* - **Cataplexy**, a symptom of narcolepsy, is characterized by sudden muscle weakness triggered by strong emotions. - It is typically managed with medications like **sodium oxybate** or certain antidepressants (e.g., venlafaxine), not liothyronine.

Q: Mechanism of action of Teriparatide?

Stimulates osteoblast activity and increases bone formation. ***Stimulates osteoblast activity and increases bone formation*** - **Teriparatide** is a recombinant form of **parathyroid hormone (PTH)**. When administered intermittently, it primarily **stimulates osteoblasts** to form new bone, leading to increased bone density and strength. - This anabolic effect makes it effective in treating **osteoporosis** by promoting bone formation rather than just inhibiting bone breakdown. *Regulates glucose metabolism and insulin sensitivity* - This mechanism describes the action of drugs such as **metformin** or **GLP-1 agonists**, which are used in the treatment of **diabetes mellitus**. - **Teriparatide** is not involved in glucose regulation or insulin sensitivity. *Stimulates lactation and affects reproductive hormones* - This mechanism is characteristic of hormones like **prolactin** or drugs that modulate **gonadotropin-releasing hormone (GnRH)**, which are involved in reproductive health. - **Teriparatide's** primary role is bone metabolism, not lactation or reproductive hormone modulation. *Inhibits osteoclast activity and decreases bone resorption* - This mechanism describes the action of **bisphosphonates** or **calcitonin**, which are anti-resorptive agents used to treat osteoporosis by reducing the breakdown of bone. - **Teriparatide**, in contrast, has an overall **anabolic effect** on bone by stimulating bone formation, even though continuous PTH elevation can cause osteoclast activity.

Q: Which of the following antithyroid medications had the maximum chances of causing agranulocytosis?

Carbimazole. ***Carbimazole*** - **Carbimazole** has the **highest reported incidence of agranulocytosis** among antithyroid drugs (approximately **0.3-0.5%**) - Although a prodrug of methimazole, **carbimazole itself** appears to confer additional risk beyond its active metabolite - **Agranulocytosis** typically occurs within the **first 2-3 months** of therapy and requires immediate discontinuation - Patients should be counseled to report **sore throat, fever, or mouth ulcers** immediately *Methimazole* - Has a **lower incidence** of agranulocytosis compared to carbimazole (approximately **0.1-0.3%**) - Once carbimazole is metabolized to methimazole, the risk profile changes - Still requires monitoring for this serious adverse effect *Propylthiouracil* - Has **comparable or slightly higher** agranulocytosis risk than methimazole but **lower than carbimazole** - More commonly associated with **hepatotoxicity** (including fulminant hepatic failure) - Preferred in **first trimester of pregnancy** and **thyroid storm** despite its risks *Iodide* - Works by **Wolff-Chaikoff effect** (inhibits thyroid hormone synthesis and release) - Does **not cause agranulocytosis** - Main adverse effects include **iodism**, hypothyroidism, and **Jod-Basedow phenomenon** (iodine-induced hyperthyroidism)

Q: Which of the following is/are side effect(s) of growth hormone administration?

All of the above. ***All of the above*** - **Growth hormone (GH)** administration can lead to a variety of side effects, including **pain at the injection site**, **glucose intolerance**, and **hypothyroidism**. - These side effects are important considerations when managing patients receiving GH therapy. *Pain at injection site* - This is a common local side effect due to the injection method itself and the substance being administered. - It is typically mild and transient but can affect patient adherence to treatment. *Glucose intolerance* - Growth hormone has **anti-insulin effects**, which can lead to **insulin resistance** and increased blood glucose levels. - This can worsen pre-existing diabetes or induce **glucose intolerance** in susceptible individuals. *Hypothyroidism* - Growth hormone can influence thyroid function, sometimes reducing the conversion of **thyroxine (T4)** to **triiodothyronine (T3)**. - This may lead to **central hypothyroidism** or exacerbate subclinical hypothyroidism, requiring thyroid hormone supplementation.

Q: What is the mechanism of action of Voglibose?

Alpha-glucosidase inhibitor. ***Alpha-glucosidase inhibitor*** - Voglibose acts by **inhibiting alpha-glucosidase enzymes** in the small intestine (maltase, sucrase, glucoamylase), which are responsible for breaking down complex carbohydrates into absorbable monosaccharides. - This delaying effect on carbohydrate digestion and absorption leads to a **reduction in postprandial glucose levels**, making it useful for managing type 2 diabetes. - The **alpha-specificity** is clinically important as it distinguishes this drug class from other enzyme inhibitors. *Beta-galactosidase inhibitor* - **Beta-galactosidase** is involved in the breakdown of lactose into glucose and galactose. - Inhibiting this enzyme would primarily affect **lactose digestion**, which is not the mechanism of Voglibose. - This is a completely different enzyme system unrelated to diabetes management. *Lactase inhibitor* - **Lactase** is a specific type of beta-galactosidase that breaks down lactose in the intestine. - Lactase inhibition would cause lactose intolerance symptoms, not affect glucose metabolism. - This does not describe the **carbohydrate-digesting enzyme inhibition** characteristic of Voglibose. *Glucosidase inhibitor* - While **technically accurate** (Voglibose does inhibit glucosidases), this term is **too general and non-specific** for pharmacological precision. - There are multiple types of glucosidases (alpha and beta) with different substrates and functions. - In pharmacology, specifying **alpha-glucosidase** is essential because it identifies the **exact enzyme target** and mechanism, which is critical for understanding drug action, side effects, and clinical use. - The best answer requires the most precise and clinically relevant terminology.

Q: Which of the following drug classes is INCORRECTLY matched with its mechanism of action?

Biguanides - AMPK activation. ***Biguanides - AMPK activation*** - This statement describes an **INCORRECT** mechanism. - While metformin does have effects on cellular metabolism, its primary mechanism is **inhibition of mitochondrial complex I**, leading to decreased hepatic gluconeogenesis. - AMPK activation is a **downstream effect**, not the primary mechanism of action. - This is the incorrectly matched pair. *Alpha-glucosidase inhibitors - Delay carbohydrate absorption* - This statement describes the **correct** mechanism of action for alpha-glucosidase inhibitors. - They work by inhibiting enzymes (alpha-glucosidases) in the small intestine that break down complex carbohydrates into absorbable monosaccharides, thus **delaying glucose absorption**. *Sulfonylureas - Block ATP-sensitive K+ channels* - This statement describes the **correct** mechanism of action for sulfonylureas. - Sulfonylureas bind to and **close ATP-sensitive potassium channels** on pancreatic beta cells, leading to depolarization and increased insulin release. *DPP-4 inhibitors - Inhibit incretin degradation* - This statement describes the **correct** mechanism of action for DPP-4 inhibitors. - They work by inhibiting the enzyme **dipeptidyl peptidase-4 (DPP-4)**, which is responsible for the rapid degradation of **incretin hormones** like GLP-1 and GIP.

Q: Which drug is used for the medical management of acromegaly due to small pituitary tumors?

Octreotide. ***Octreotide*** - **Octreotide** is a **somatostatin analog** and the **first-line medical therapy** for acromegaly. - It effectively suppresses **growth hormone (GH)** and **IGF-1** secretion by binding to somatostatin receptors (especially SSTR2 and SSTR5) on pituitary adenomas. - Normalizes IGF-1 levels in **50-70%** of patients and can reduce tumor size. - Used for small or large tumors when surgery is not feasible, has failed, or as primary medical management. *Cabergoline* - **Cabergoline** is a **dopamine agonist** with limited efficacy in acromegaly. - Controls GH/IGF-1 in only **10-20%** of patients, primarily those with **co-secretion of prolactin** (mixed GH-PRL adenomas). - May be used as **adjunctive therapy** with somatostatin analogs but is not first-line treatment. *Pegvisomant* - **Pegvisomant** is a **GH receptor antagonist** that blocks GH action at the tissue level. - Highly effective at normalizing **IGF-1** levels (**>90%** of patients). - Used as **second-line therapy** when somatostatin analogs fail or are insufficient. - Does not reduce tumor size or GH secretion directly. *Vigabatrin* - **Vigabatrin** is an **antiepileptic drug** that inhibits GABA transaminase. - Has no role in the treatment of acromegaly or pituitary tumors.

Q: What is the mechanism of action of Pegvisomant?

GH receptor antagonist. ***GH receptor antagonist*** - Pegvisomant is a **growth hormone (GH) receptor antagonist** that binds to GH receptors but does not activate them. - This action blocks the binding of endogenous GH to its receptors, thereby inhibiting the downstream production of **insulin-like growth factor 1 (IGF-1)** and reducing the symptoms of **acromegaly**. *Somatostatin antagonist* - **Somatostatin analogues** (e.g., octreotide, lanreotide) are used to treat acromegaly by inhibiting the release of growth hormone from the pituitary gland. - Pegvisomant does not act on somatostatin receptors; it functions at the level of the **GH receptor**. *Somatotropin antagonist* - **Somatotropin** is another name for **growth hormone (GH)**. - While Pegvisomant opposes the action of somatotropin, its mechanism is specifically at the receptor level, making "GH receptor antagonist" a more precise description. *GH receptor agonist* - A **GH receptor agonist** would stimulate the growth hormone receptor, leading to increased IGF-1 production and exacerbating conditions like acromegaly. - Pegvisomant has the opposite effect, blocking GH action rather than promoting it, making it an **antagonist**.

Question 1

Which Selective Estrogen Receptor Modulator (SERM) is used in the treatment of Dysfunctional Uterine Bleeding (DUB)?

Accepted Answer

Ormiloxifene

Answer

Clomiphene

Answer

Raloxifene

Answer

Tamoxifen

Question 2

Which of the following are medical management options for hyperparathyroidism?

Accepted Answer

All of the options

Answer

Bisphosphonates

Answer

Calcitonin

Answer

Plicamycin

Question 3

What is a therapeutic indication for the use of liothyronine?

Accepted Answer

Resistant depression

Answer

Social phobia

Answer

Cataplexy

Answer

Alzheimer's disease

Question 4

Mechanism of action of Teriparatide?

Accepted Answer

Stimulates osteoblast activity and increases bone formation

Answer

Stimulates lactation and affects reproductive hormones

Answer

Regulates glucose metabolism and insulin sensitivity

Answer

Inhibits osteoclast activity and decreases bone resorption

Question 5

Which of the following antithyroid medications had the maximum chances of causing agranulocytosis?

Accepted Answer

Carbimazole

Answer

Iodide

Answer

Propylthiouracil

Answer

Methimazole

Question 6

Which of the following is/are side effect(s) of growth hormone administration?

Accepted Answer

All of the above

Answer

Hypothyroidism

Answer

Pain at injection site

Answer

Glucose intolerance

Question 7

What is the mechanism of action of Voglibose?

Accepted Answer

Alpha-glucosidase inhibitor

Answer

Beta-galactosidase inhibitor

Answer

Lactase inhibitor

Answer

Glucosidase inhibitor

Question 8

Which of the following drug classes is INCORRECTLY matched with its mechanism of action?

Accepted Answer

Biguanides - AMPK activation

Answer

Alpha-glucosidase inhibitors - Delay carbohydrate absorption

Answer

Sulfonylureas - Block ATP-sensitive K+ channels

Answer

DPP-4 inhibitors - Inhibit incretin degradation

Question 9

Which drug is used for the medical management of acromegaly due to small pituitary tumors?

Accepted Answer

Octreotide

Answer

Vigabatrin

Answer

Pegvisomant

Answer

Cabergoline

Question 10

What is the mechanism of action of Pegvisomant?

Accepted Answer

GH receptor antagonist

Answer

Somatostatin antagonist

Answer

Somatotropin antagonist

Answer

GH receptor agonist

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?